183 related articles for article (PubMed ID: 23909028)
21. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Zhang B
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
[No Abstract] [Full Text] [Related]
22. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
Voduc D; Nielsen TO
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
24. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
[TBL] [Abstract][Full Text] [Related]
25. [MicroRNA and breast cancer-related hormone receptors].
ZHANG J; NIU Y; YU Q
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):212-4. PubMed ID: 21575403
[No Abstract] [Full Text] [Related]
26. Breast cancer molecular subtypes--modern therapeutic concepts for targeted therapy of a heterogeneous entity.
Liedtke C; Kiesel L
Maturitas; 2012 Dec; 73(4):288-94. PubMed ID: 23020990
[TBL] [Abstract][Full Text] [Related]
27. Triple-negative breast cancer: making the most of a misnomer.
McCarthy N; Mitchell G; Bilous M; Wilcken N; Lindeman GJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):145-55. PubMed ID: 22524573
[TBL] [Abstract][Full Text] [Related]
28. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Jagiello-Gruszfeld A; Tjulandin S; Dobrovolskaya N; Manikhas A; Pienkowski T; DeSilvio M; Ridderheim M; Abbey R
Oncology; 2010; 79(1-2):129-35. PubMed ID: 21088439
[TBL] [Abstract][Full Text] [Related]
29. [Molecular phenotypes of breast cancer and their clinical application].
Tang P; Wei B; Hicks DG; Skinner K; Bu H
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):13-7. PubMed ID: 19489219
[No Abstract] [Full Text] [Related]
30. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
[TBL] [Abstract][Full Text] [Related]
31. Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies.
Viale G; Ghioni M; Mastropasqua MG
Curr Opin Oncol; 2010 Nov; 22(6):541-6. PubMed ID: 20827197
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
Gonçalves A; Deblock M; Esterni B; Tarpin C; Bertucci F; Gilabert M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G; Extra JM; Viens P
Anticancer Drugs; 2009 Nov; 20(10):946-52. PubMed ID: 19741502
[TBL] [Abstract][Full Text] [Related]
33. Targeting survivin's co-conspirators: do alternative methods of trapping survivin in the nucleus have potential in triple-negative breast cancer therapy?
Holloway MP; Altura RA
Future Oncol; 2012 Aug; 8(8):907-9. PubMed ID: 22894664
[No Abstract] [Full Text] [Related]
34. Triple-negative breast cancer: role of the androgen receptor.
Gucalp A; Traina TA
Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
[TBL] [Abstract][Full Text] [Related]
35. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
[TBL] [Abstract][Full Text] [Related]
36. [Molecular subtypes and individualized treatment of breast cancer].
Xu BH; Zhang P
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
[No Abstract] [Full Text] [Related]
37. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with bone metastasis in breast cancer: a preliminary study in an Indonesian population.
Irawan C; Hukom R; Prayogo N
Acta Med Indones; 2008 Oct; 40(4):178-80. PubMed ID: 19153424
[TBL] [Abstract][Full Text] [Related]
39. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
40. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
Tuma RS
J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]